Garvey WT, et al. - This trial was formulated in order to inspect the effects of canagliflozin in contrast with glimepiride on select adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes. An improvement could be found in the adipose tissue function and along with an induction of changes in serum leptin, adiponectin, and IL-6 due to canagliflozin. This, in turn, could favorably affect the insulin sensitivity and cardiovascular disease risk.